Fresenius Kabi Launches Tyenne®, the First Tocilizumab Biosimilar
Fresenius Kabi has launched its tocilizumab biosimilar, Tyenne®, which references Actemra®** (tocilizumab), making it the first and only tocilizumab biosimilar available in Canada.
Tyenne® is approved for the treatment of various inflammatory and immune diseases, including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA), cytokine release syndrome (CRS), and for COVID-19 treatment.
Offering a cost-effective alternative to higher-priced biologic therapies, Tyenne® is a beneficial solution for the healthcare system, with all ten provinces supporting the transition to biosimilars.
As a biosimilar to the reference biologic drug Actemra®, Tyenne® belongs to the interleukin-6 (IL-6) receptor blocker class, providing Canadian patients with increased access to affordable treatment options.
Tyenne® is available in user-friendly administration formats, including subcutaneous options (prefilled syringes and autoinjectors) as well as intravenous vials, offering flexibility for patients and healthcare providers.
